HENDERSON, Nev.–(Business enterprise WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical corporation targeted on novel and specific oncology therapies, introduced now that management will current an overview of the company’s business enterprise system and growth-stage applications at two future digital trader conferences:
- Jefferies Virtual Healthcare Meeting 2021. A fireplace chat presentation is scheduled for Thursday, June 3, 2021, at 9:30 a.m. ET.
- JMP Securities Everyday living Sciences Meeting 2021. A fireside chat presentation is scheduled for Wednesday, June 16, 2021, at 1:30 p.m. ET.
A reside webcast of every single presentation will be out there from the Investor Relations area of the company’s website at http://trader.sppirx.com/occasions-and-displays with a replay readily available shortly after each celebration.
About Spectrum Prescribed drugs, Inc.
Spectrum Prescription drugs is a biopharmaceutical company centered on getting, developing, and commercializing novel and qualified oncology therapies. Spectrum has a sturdy keep track of document of productively executing throughout the biopharmaceutical company product, from in-licensing and getting differentiated medicines, clinically developing novel assets, efficiently attaining regulatory approvals and commercializing in a aggressive health care market. Spectrum has a late-phase pipeline with novel property that serve spots of unmet will need. This pipeline has the prospective to remodel the business in the in the vicinity of foreseeable future. For extra information and facts on Spectrum Prescribed drugs you should visit www.sppirx.com.
Forward-searching statement — This push launch may well comprise forward-seeking statements concerning potential activities and the long term performance of Spectrum Prescribed drugs that require hazards and uncertainties that could cause real benefits to vary materially. These statements are centered on management’s current beliefs and anticipations. These statements contain, but are not constrained to, statements that relate to Spectrum’s business enterprise and its foreseeable future, which includes selected business milestones, Spectrum’s potential to identify, purchase, build and commercialize a wide and numerous pipeline of late-stage scientific and commercial products, the timing and success of Fda conclusions, and any statements that relate to the intent, belief, plans or anticipations of Spectrum or its administration, or that are not a assertion of historic truth. Risks that could induce precise results to vary incorporate the risk that Spectrum’s current and new drug candidates could not verify secure or helpful, the likelihood that our current and new purposes to the Food and drug administration and other regulatory businesses could not get acceptance in a timely method or at all, the likelihood that our present and new drug candidates, if accepted, may perhaps not be extra helpful, safer or much more charge economical than competing drugs, the risk that our efforts to get or in-license and establish further drug candidates could fall short, our dependence on third functions for scientific trials, production, distribution and quality manage and other pitfalls that are described in additional depth in the company’s reports filed with the Securities and Trade Fee. The company does not program to update any these kinds of forward-hunting statements and expressly disclaims any obligation to update the information contained in this press release apart from as essential by law.
SPECTRUM Prescription drugs, INC.® is a registered trademark of Spectrum Prescription drugs, Inc and its affiliate. REDEFINING Cancer CARE™ and the Spectrum Prescription drugs logos are logos owned by Spectrum Prescription drugs, Inc. Any other emblems are the assets of their respective proprietors.
© 2021 Spectrum Pharmaceuticals, Inc. All Legal rights Reserved